JC05 Rec'd PCT/PTO 03 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Cosford, et al.	1	0/552362
	to be assigned RYLSUBSTITUTED TRIAZOLE MODULATORS ETABOTROPIC GLUTAMATE RECEPTOR-5	Art Unit:	···
Commissione	r for Patents		

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

P.O. Box 1450

Alexandria, Virginia 22313-1450

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By _____ Date ____

JC05 Rec'd PCT/PTO 03 OCT 2005 PATENT Case No. MS0036YP

FILING DATE

RELATED APPLICATION

MERCK CASE

INFORMATION DISCLOSURE STATEMENT 10/552362

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER

		 	
If th	is is inconvenient, additional copies will be submitted upon reques	st.	
6	6. In accordance with 37 C.F.R. 1.97, (check one)		
\checkmark	the attached information is filed within three months of the filing da	ate of the captioned case.	
	the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the m	ailing of a first
	the attached information is filed before the mailing of a first Office examination under §1.114.	action after the filing of a re	equest for continued
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final of the otherwise closes prosecution in the application. The enclosed authorized No. 13-2755 for the fee required under 37 C.F.R. 1.17(p)	Action, Notice of Allowance thorization is therefore give	, or an action that
	each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application no Statement.		
	each item of information contained in the information disclosure so from a foreign patent office in a counterpart application and this condesignated in §1.56(c) more than thirty days prior to the filing of the	ommunication was not rece	ived by any individual
	no item of information contained in this Information Disclosure Statement office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual desimonths prior to the filing of this Statement.	e knowledge of the person	signing the certification
		Respectfully submitted,	_

By: David A. Rubin

Attorney For Applicant(s)

Reg. No. 40,314

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-<u>2675</u>

Date: October 3, 2005

JC05 Rec'd PCT/BY A through 33 O.C. TMB 201073 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Abordent

r PTO/SB/08A (07-05),	Information Disclosure Statement by Applicant	
Patent and Trademark	Office: U.S DEPARTMENT OF COMMERCE	

* Substitute → r form 1449A/PTO INFORMATION DISCLOSURE				COMPLETE IF KNOWN			
				Application Number	48.5507/9		
C	TATENTENIO DE	. A TO	DI ICANT	Filing Date	<u> 10/552362 - </u>		
3	TATEMENT BY	AP	PLICANI	First Named Inventor			
			,	Group Art Unit			
	(use as many sheets as necessary)			Examiner Name			
Sheet	1	of	2	Attorney Docket Number	MS0036YP		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
					05/30/2000		
. ,							
			 	·			
					•		
			-				
			-				
	-			<u> </u>			
			_				
		<u> </u>					
			_				

	FOREIGN PATENT DOCUMENTS								
			Foreign Patent Document			Date of Publication of			
Examiner Initials*	Cite No.	Office	e Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY			
	A1		WO 03/051315 A2		Cosford, et al.	06/26/2003			
	ļ								
	<u> </u>				·				
<u> </u>				ļ					
ļ									
		<u> </u>							
<u> </u>	<u></u>	L							

Examiner Signature Date Considered	-

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	bstitute for form 1449B/PTO	DIS	CLOSURE	Application ACOS REC'T PTO 03 OCT 2005			
C	TATEMENT DSZ	A D	DI ICANIT	Filing Date	10/552362		
STATEMENT BY APPLICANT				First Named Inventor			
	(Group Art Unit			
(use as many sheets as necessary)			ecessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	MS0036YP		

_	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	A2	Revesz. et al., SAR of 2,6-Diamino-3,5-difluoropyridinyl Substituted Heterocycles as Novel p38 MAP Kinase Inhibitors, Bioorganic & Medicinal Chemistry Letters, 12 (2002) 2109-2112.				

~	Date Considered
---	--------------------

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.